Protein that stem cells require could be a target in killing breast cancer cells – Science Daily
|
Protein that stem cells require could be a target in killing breast cancer cells
Science Daily When a stem cell differentiates, it starts down a one-way path that will result in its specialization and eventually its death. For instance, a stem cell in the breast can become a luminal cell, one of the breast’s “milk factories.” Such cells have a … |
Fox News |
Immunotherapy Combination Shows Promise in Early Stage Triple Negative Breast Cancer
Newswise (press release) By combining chemotherapy with immunotherapy in this clinical trial, we are extending our options for treatment, and finding new hope,” said Dr. Pusztai. The phase I part of the trial sought to determine the safety and tolerability of durvalumab in … As scientists train the immune system to fight cancer, others look to combat costsMedical Xpress |
Fox News |
Immunotherapy Combination Shows Promise in Early Stage Triple Negative Breast Cancer
Newswise (press release) By combining chemotherapy with immunotherapy in this clinical trial, we are extending our options for treatment, and finding new hope,” said Dr. Pusztai. The phase I part of the trial sought to determine the safety and tolerability of durvalumab in … As scientists train the immune system to fight cancer, others look to combat costsMedical Xpress |
Futurism |
China Is About to Begin the World’s First Clinical Trial With Embryonic Stem Cells
Futurism Two clinical trials will begin using embryonic stem cells in China to treat Parkinson’s disease and blindness. These trials represent a new set of regulations on embryonic stem cells in China and possibly a new era of research around the world. |
|
Triple Immunotherapy Combo to Be Tested in Trial with Bladder Cancer Patients
Immuno-Oncology News Two immunotherapies, INO–5401 and INO–9012, will be combined with immune checkpoint inhibitor Tecentriq (atezolizumab) in a Phase 1/2 trial to test the combo’s safety and effectiveness in treating advanced bladder cancer. The trial, a result of … |
FiercePharma |
PARP, IDO, CAR–T and more: What we’re watching for at #ASCO17
FiercePharma Nanjing Legend Biotech is looking to set out a new-type of CAR–T cell therapy in relapsed/refractory multiple myeloma for LCAR-B38M in an early-to-midstage trial. Its ongoing trial is primarily set up to assess any treatment-related AEs, but secondary … |
FiercePharma |
PARP, IDO, CAR–T and more: What we’re watching for at #ASCO17
FiercePharma Nanjing Legend Biotech is looking to set out a new-type of CAR–T cell therapy in relapsed/refractory multiple myeloma for LCAR-B38M in an early-to-midstage trial. Its ongoing trial is primarily set up to assess any treatment-related AEs, but secondary … |